Answers are grounded in this paper and cite their sources.
Background Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited. Methods A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index mortality data for patients initiating nivolumab monotherapy during 2019–2023. Overall survival (OS), time to treatment discontinuation (TTD), and dispensing‐based proxies for potential immune‐related adverse events (irAEs) were assessed. Results Among 1398 patients, median OS was 9.3 months and TTD was 7.8 months. Median OS was longer in males than females (10.0 vs. 7.7 months, p = 0.049), while patients with prior corticosteroid exposure had shorter OS than those without (8.3 vs. 11.5 months; aHR 1.20, 95% CI: 1.06–1.36). Incident corticosteroid and levothyroxine use occurred in 10.3% and 10.9% of patients, respectively. Conclusions Real‐world outcomes were comparable to clinical trial findings, supporting nivolumab's effectiveness in Australian clinical practice.
No takes yet. Share an insight, caveat, or question.
Sault et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: